The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,514.00
Bid: 12,512.00
Ask: 12,516.00
Change: -76.00 (-0.60%)
Spread: 4.00 (0.032%)
Open: 12,626.00
High: 12,646.00
Low: 12,488.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 flat, peers and pound up before US data

Thu, 10th Aug 2023 11:59

(Alliance News) - London's FTSE 100 underwhelmed on Thursday, as a slew of its heavyweights went ex-dividend, though blue-chip equities in mainland Europe were higher, showing no signs of pre-US inflation data angst and overlooking an acceleration in tensions between the world's two largest economies.

The FTSE 100 index went into Thursday afternoon just 3.58 points lower at 7,583.72. The FTSE 250 was down just 4.05 points at 18,933.15, and the AIM All-Share was down 1.69 points, 0.2%, at 756.29.

The Cboe UK 100 was up 0.1% at 756.47, the Cboe UK 250 was up 0.3% at 16,637.94, and the Cboe Small Companies was up 0.1% at 13,610.77.

In European equities on Thursday, the CAC 40 in Paris was up 0.8%, while the DAX 40 in Frankfurt was 0.3% higher.

Ahead of the US inflation data reported at 1330 BST, the dollar was largely weaker.

The pound was quoted at USD1.2772 early Thursday afternoon in London, climbing from USD1.2717 at the London equities close on Wednesday. The euro traded at USD1.1027, up from USD1.0977. Against the yen, the dollar rose to JPY143.80, from JPY143.60.

According to FXStreet cited consensus, the US annual inflation rate is expected to heat up to 3.3%, from 3.0% in June. The core inflation rate, which excludes food and energy, is expected to remain at 4.8%.

"The last reading provided a positive surprise as it undershot expectations for the first time in a long time. A repeat could revive a flagging equity rally, but a negative shock could accelerate recent selling," AJ Bell analyst Russ Mould commented.

A hotter-than-expected reading could mean the Federal Reserve continues with its hiking cycle.

Oanda analyst Craig Erlam commented: "It will take something big for the Fed to consider hiking again you would think, having shifted to a more gradual approach in recent months."

In London, share price falls of 1.2% and 1.3% for lenders HSBC and NatWest, 1.1% for drugmaker AstraZeneca and 3.0% for miner Rio Tinto hurt the FTSE 100. The stocks went ex-dividend, meaning new buyers do not qualify for the latest payouts.

Spirax-Sarco fell 5.0%, sitting at the bottom of the large-cap index.

The Cheltenham, England-based thermal energy management and pumping company said pretax profit fell 18% to GBP114.0 million, from GBP138.5 million a year ago.

The firm reported revenue of GBP850.8 million in the first half of 2023, up 13% from GBP750.1 million the year prior.

Spirax warned destocking in Biopharm, which refers to sales from the Watson-Marlow division to pharma and biotech, "is now expected to continue into 2024".

Looking ahead, the company said it expects its revenue group sales to be between flat and 4% higher for the year, when compared to 2022's pro-forma sales of GBP1.73 billion. Back in a May trading update, it predicted "double-digit sales growth for the group in 2023, representing mid-single-digit sales growth over 2022 pro-forma sales".

Savills slumped 8.7% as it reported a decline in first-half earnings.

The estate agent said pretax profit in the half-year ended June 30 plunged 88% to GBP6.0 million from GBP50.4 million 12 months earlier. Revenue declined 2.5% to GBP1.01 billion from GBP1.04 billion.

Chief Executive Mark Ridley said: "Savills has weathered both the inflationary cost conditions and reduced transaction volumes well, increasing market share and, supported by our strong balance sheet, continuing to undertake selective business development activities to further the group's long term growth strategy. We are seeing some positive signs in markets such as the UK and continued strength in certain Asia Pacific markets including Japan; in Continental Europe and mainland China we now expect reduced market volumes to continue through much of the year."

Elsewhere in London, Eco Atlantic jumped 12%, as it struck a deal to buy Tullow Oil's stake in a block in Guyana. Tullow was 1.2% higher.

Oil and gas explorer Eco will buy an additional 60% stake in the Orinduik block and will hold 75% as a result. TOQAP Guyana, a joint venture between TotalEnergies and QatarEnergy owns the remainder. Tullow no longer has a stake.

Eco Atlantic will pay USD700,000 to Tullow upfront, USD4 million in the event of commercial discovery and USD10 million upon the issue of a production licence from the government of Guyana. In addition, Tullow will have a royalty on future output.

Analysts at Peel Hunt commented: "We see this as a good deal for both parties, as it allows Tullow to continue to focus on its strategy of monetising its high-quality production assets with continued exposure to Guyana upside, while exploration-focused Eco has picked up a material stake in this high-potential licence for a relatively small upfront consideration. The deal also gives Eco additional optionality with regards bringing a new partner into the licence."

Stocks in New York are called to open higher on Thursday. Both the Dow Jones Industrial Average and S&P 500 are called up 0.5%, and the Nasdaq Composite 0.6% higher.

Beijing hit back on Thursday after the US restricted investments in Chinese technology.

US President Joe Biden hours earlier announced an executive order directing the Treasury Department to restrict certain US investments in China in sensitive high-tech sectors including semiconductors, quantum computing and artificial intelligence.

China's foreign ministry blasted the move as an attempt to "engage in anti-globalisation and de-sinicisation", warning that China would "resolutely safeguard its own rights and interests".

Analysts at UBS commented: "We expect tensions in the US-China bilateral relationship to remain elevated. A regime of increasing restrictions on technology transfer and capital flows between the two nations is likely to take hold and become a persistent irritant."

Gold was quoted at USD1,922.05 an ounce early Thursday afternoon, rising from USD1,916.66 on Wednesday. Brent oil was trading at USD87.38 a barrel, higher than USD86.92.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.